Prévost G, Provost P, Sallé V, Lanson M, Thomas F
Institut d'Oncologie Cellulaire et Moléculaire Humaine, Université Paris-Nord, Bobigny, France.
Eur J Cancer. 1993;29A(11):1589-92. doi: 10.1016/0959-8049(93)90300-5.
Hypothalamic somatostatin and its synthetic analogues inhibit the cell growth of several tumour models. The somatostatin analogue lanreotide (somatuline or BIM23014C) inhibits both the in vivo and in vitro cell growth of various mammary tumours. In order to evaluate the presence of receptors for lanreotide in breast tissue, samples from 41 female and 2 male patients were analysed by a cross-linking assay. All the samples examined possessed at least one subtype of lanreotide binding polypeptide, however, different polypeptide patterns were observed. The two major complexes had molecular weights of 57 kD and 42 kD. The previously demonstrated antiproliferative activity of lanreotide and the high percentage of positive tumours supports the use of lanreotide in clinical trials. However, the role of each receptor subtype in the control of breast cell proliferation requires further characterisation.
下丘脑生长抑素及其合成类似物可抑制多种肿瘤模型的细胞生长。生长抑素类似物兰瑞肽（索马杜林或BIM23014C）可抑制各种乳腺肿瘤的体内和体外细胞生长。为评估乳腺组织中兰瑞肽受体的存在情况，采用交联分析法对41例女性和2例男性患者的样本进行了分析。所有检测样本均至少拥有一种兰瑞肽结合多肽亚型，然而，观察到了不同的多肽模式。两种主要复合物的分子量分别为57 kD和42 kD。先前证实的兰瑞肽抗增殖活性以及高比例的阳性肿瘤支持在临床试验中使用兰瑞肽。然而，每种受体亚型在控制乳腺细胞增殖中的作用需要进一步明确。
